Summit partner Akeso reports positive OS for ivonescimab in HARMONi-2 vs pembrolizumab

Summit Therapeutics Inc.

Akeso's HARMONi-2: statistically significant OS improvement for ivonescimab vs pembrolizumab in PD-L1-positive advanced NSCLC.
Primary PFS analysis earlier: HR 0.51 (95% CI 0.38-0.69; p<0.0001) by IRRC; OS data to be presented at upcoming medical conference.
Ivonescimab was approved by China's NMPA in April 2025 based on HARMONi-2; Summit holds license rights in US/Europe where it remains investigational.
Summit is conducting HARMONi-7 in PD-L1 high-expressing NSCLC.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.